synthetic peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
=== Biomolecular research === Researchers often use heterologous expression techniques to study protein interactions. For example, bacteria has been optimized in the heterologous expression and biosynthesis of nitrogenase through NifEN. This is able to be expressed and engineered in E.coli. Through this host, it remains exceedingly challenging to heterologously express a complex, heteromultimeric metalloprotein like NifEN with a full complement of subunits, metalloclusters, and functionality. The NifEN variant engineered in this bacterial host can retain its cofactor efficacy at analogous cofactors-binding sites, which provide proof for heterologous expression and encourage future investigation of this metalloenzyme. Additionally, there have been recent reports of the utility of new filamentous fungal systems in the production of industrial proteins. Advantages include high transformation frequencies, the production of proteins at neutral pH, low viscosity of the fermentation broth due to strain selection for a nonfilamentous format and short fermentation times. Many human gene products, such as albumin, IgG, and interleukin 6, have been expressed in heterologous systems with varying degrees of success. Inconsistent results have hinted at a shift from gene-by-gene studies to a whole-organism approach to post-translational modification. Oocytes are readily optimized for their large size and translational capacity, which is able to observe integrated cell responses.
The study of the effect of infectious agents on metabolism is still in its early stages. Gut flora has been shown to differ between lean and obese people. There is an indication that gut flora can affect the metabolic potential. This apparent alteration is believed to confer a greater capacity to harvest energy contributing to obesity. Whether these differences are the direct cause or the result of obesity has yet to be determined unequivocally. The use of antibiotics among children has also been associated with obesity later in life. An association between viruses and obesity has been found in humans and several different animal species. The amount that these associations may have contributed to the rising rate of obesity is yet to be determined.
The Russell 2000 is a stock market index tracking the stock performance of 2,000 companies listed on stock exchanges in the United States that are considered to have small market capitalizations. The Russell 2000 is a subset of the Russell 3000. It is maintained by FTSE Russell and its components are determined via strict rules-based methodology, with an annual rebalancing in late June, the only time new entrants are added to the index. The index is a public-float-weighted/capitalization-weighted index. The index includes approximately 5% of the total market capitalization of U.S. public companies, with an aggregate market capitalization of about $3.5 trillion as of June 30, 2026. The median market capitalization of the components of the index is $1.1 billion and components range in market capitalization from $146 million to $2.7 billion. Products linked to the Russell 2000 include index funds (exchange-traded funds/ETFs and mutual funds) as well as derivatives (options and futures contracts), which are available for trading in many countries with the goal of replicating the performance of the index. Also available are modified index funds; they replicate the performance of the index with modifications such as the use of covered call strategies, equal weighting, performance buffers, leverage, inclusion of only growth or value stocks, or exclusion of certain sectors, all with the goal of changing the risk/return and yield.
Transfer of sulfur-containing groups is covered by EC 2.8 and is subdivided into the subcategories of sulfurtransferases, sulfotransferases, and CoA-transferases, as well as enzymes that transfer alkylthio groups. A specific group of sulfotransferases are those that use PAPS as a sulfate group donor. Within this group is alcohol sulfotransferase which has a broad targeting capacity. Due to this, alcohol sulfotransferase is also known by several other names including "hydroxysteroid sulfotransferase," "steroid sulfokinase," and "estrogen sulfotransferase." Decreases in its activity has been linked to human liver disease. This transferase acts via the following reaction: 3'-phosphoadenylyl sulfate + an alcohol
Certain serpins spontaneously undergo the S to R transition without having been cleaved by a protease, to form a conformation termed the latent state. Latent serpins are unable to interact with proteases and so are no longer protease inhibitors. The conformational change to latency is not exactly the same as the S to R transition of a cleaved serpin. Since the RCL is still intact, the first strand of the C-sheet has to peel off to allow full RCL insertion. Regulation of the latency transition can act as a control mechanism in some serpins, such as PAI-1. Although PAI-1 is produced in the inhibitory S conformation, it "auto-inactivates" by changing to the latent state unless it is bound to the cofactor vitronectin. Similarly, antithrombin can also spontaneously convert to the latent state, as an additional modulation mechanism to its allosteric activation by heparin. Finally, the N-terminus of tengpin, a serpin from Thermoanaerobacter tengcongensis, is required to lock the molecule in the native inhibitory state. Disruption of interactions made by the N-terminal region results in spontaneous conformational change of this serpin to the latent conformation.
Sources: en.wikipedia.org
==== Estonia ==== In April 2007, Estonia came under cyber attack in the wake of relocation of the Bronze Soldier of Tallinn. The largest part of the attacks were coming from Russia and from official servers of the authorities of Russia. In the attack, ministries, banks, and media were targeted. This attack on Estonia, a seemingly small Baltic state, was so effective because of how most of Estonian government services are run online. Estonia has implemented an e-government, where banking services, political elections, taxes, and other components of a modern society are now all done online.
Senate on 17 May 2005, Galloway said that he had "met Saddam Hussein exactly the same number of times as Donald Rumsfeld met him," but "The difference is Donald Rumsfeld met him to sell him guns ... I met him to try to bring about an end to sanctions, suffering and war". In the late 1990s, Galloway allegedly lost favour with Saddam Hussein after telling an interviewer that he supported the Iraqi people rather than their president. In 1999, he met with Uday Hussein, Saddam's son. On 6 May 2002, Galloway met with Deputy Prime Minister Tariq Aziz in Baghdad on his second visit to Iraq that year, accompanied by the Labour peer Nicolas Rea and Labour MPs Kerry Pollard and Robert Wareing. He was also scheduled to address a conference of solidarity with the Iraqi people. His party ran into the far-right Governor of Carinthia Jörg Haider returning from a meeting with Foreign Minister Naji Sabri. Galloway did not take his companions' suggestion to copy a scene from Casablanca by singing La Marsellaise in front of Haider. On 8 August 2002, two days after the Iraqi invitation to resume talks in Baghdad was rejected by the United Nations Security Council and against the mounting threat of US invasion, Galloway was received for the second time by Saddam Hussein. Per Galloway's account, the meeting took place in a secret underground bunker near Baghdad.
For years I have been endeavouring to find a credible thesis for the development of Buddhist art, and primarily to trace the ancient route by which the art of imperial Rome, etc..., reached the Far East. What I have seen here goes beyond my wildest dreams. If only I had hands enough to copy it all, [for] here in Kizil are about 300 caves, some of them containing frescoes, all of them very old and fine." The French explorer Paul Pelliot and his photographer Charles Nouette, who were in Kucha from January 1907, visited Kizil soon after the German mission, from September 1, 1907, over a few days, and Charles Nouette took many beautiful and informative photographs. Albert von Le Coq came back to Kizil and surrounding areas in 1913–1914, heading the Fourth German Expedition, removing many paintings, including those Grünwedel had left in place, but generally taking much fewer records than his predecessor.
=== Declined === The following notable individuals were the subject of speculation about their possible candidacy but publicly denied interest in running or were rejected as pre-candidates and declined to pursue their candidacies.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.